Galantamine inhibits β-amyloid aggregation and cytotoxicity

Matharu, Balpreet and Gibson, Gillian and Parsons, Richard and Huckerby, Thomas N and Moore, Susan A and Cooper, Leanne J and Millichamp, Robert and Allsop, David and Austen, Brian (2009) Galantamine inhibits β-amyloid aggregation and cytotoxicity. Journal of the Neurological Sciences, 280 (1-2). pp. 49-58.

Full text not available from this repository.

Abstract

The ability of galantamine (Reminyl) to inhibit the aggregation and toxicity of the beta-amyloid peptide (Abeta) was investigated. Galantamine showed concentration-dependent inhibition of aggregation of both Abeta 1-40 and Abeta 1-42, as determined by an ELISA method. Electron microscope studies of Abeta 1-40 incubated in the presence of galantamine revealed fibrils that were disordered and clumped in appearance. MTT and lactate dehydrogenase assays, employing SH-SY5Y human neuroblastoma cells, showed that galantamine reduced the cytotoxicity induced by Abeta 1-40. Galantamine also dramatically reduced Abeta 1-40-induced cellular apoptosis in these cells. There is some evidence that galantamine may not be acting purely as a symptomatic treatment. Disease-modifying effects of the drug could be due to an additional effect on Abeta aggregation and/or toxicity.

Item Type:
Journal Article
Journal or Publication Title:
Journal of the Neurological Sciences
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/2800/2808
Subjects:
?? AMYLOID BETA-PEPTIDESANALYSIS OF VARIANCEAPOPTOSISCELL LINE, TUMORCHOLINESTERASE INHIBITORSDOSE-RESPONSE RELATIONSHIP, DRUGENZYME-LINKED IMMUNOSORBENT ASSAYGALANTAMINEHUMANSL-LACTATE DEHYDROGENASEMICROSCOPY, ELECTRONMODELS, MOLECULARNEUROPROTECTIVE AGENTS ??
ID Code:
50806
Deposited By:
Deposited On:
07 Nov 2011 10:00
Refereed?:
Yes
Published?:
Published
Last Modified:
19 Sep 2023 00:45